Four Relapses in Three Years, Each After Stopping Pills: Weighing a Long-Acting Injectable Antipsychotic for a 34-Year-Old With Schizophrenia When Trials and Registries Disagree
[Student Name]
University of Phoenix
PMH/504: Psychiatric Management Of Adult And Geriatric Patients
Week 4 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Mr. K., a 34-year-old with schizophrenia for 10 years, has been hospitalized four times in three years, each time weeks after stopping oral risperidone. Between relapses he works part time at a hardware store and lives with his sister. He says he stops pills because he "forgets" and because, when well, he doubts he needs them. His sister asks whether "the shot" would help. This paper weighs the evidence.
Maintenance Treatment Works
Leucht et al. (2012) meta-analyzed 65 trials of maintenance antipsychotics versus placebo and found that relapse at one year occurred in 27% of patients taking antipsychotics compared with 64% on placebo, with a number needed to treat of three, and that readmissions were also reduced. The question for Mr. K. is not whether to take medication but how to ensure he receives it.
What the Trials Say About Injectables
Kishimoto et al. (2014) meta-analyzed 21 randomized trials comparing long-acting injectable and oral antipsychotics and found no overall difference in relapse prevention, although first-generation injectables showed an advantage in some analyses. The authors noted that randomized trials are less representative of real-world patients.
What the Registry Says
Tiihonen et al. (2017) followed 29,823 patients with schizophrenia in Sweden and found that clozapine and long-acting injectable antipsychotics were associated with the lowest risk of rehospitalization, with the risk for injectables about 20% to 30% lower than for the equivalent oral formulations.
Trials enroll people who take their pills; Mr. K. is the patient the registry describes.
Why the Evidence Disagrees
Randomized trials select patients willing to participate and monitor adherence closely, so oral medication is taken more reliably than in usual care, narrowing any difference. Registries capture patients like Mr. K., whose adherence lapses in daily life, where an injection guarantees delivery. For a patient whose relapses follow stopping pills, the real-world evidence is more relevant.
Shared Decision Making
I present the options: continuing oral risperidone with adherence supports, switching to long-acting injectable risperidone or paliperidone every two weeks to monthly, or other injectables. We discuss injection site pain, visit frequency, side effects similar to oral forms and the benefit of not needing to remember daily pills. Mr. K. worries about needles but likes the idea of not thinking about medication daily. He chooses monthly paliperidone palmitate.
Starting the Injectable
Because he has tolerated oral risperidone, he can start paliperidone palmitate with the standard loading doses in the deltoid, then monthly maintenance, with oral medication stopped according to the product's schedule. The first injections are given in clinic, and a monthly appointment is scheduled with reminders.
Addressing Needle Fear
Mr. K.'s worry about needles is common. A small needle, a deltoid site he can see and a nurse who explains each step reduce anxiety. Many patients find the monthly visit less burdensome than daily pills once the first injections are done.
Adherence Is Not a Character Flaw
Stopping medication when well often reflects reduced insight, side effects or simply forgetting, not defiance. Framing the injectable as a way to take one task off his daily list, rather than as a response to failure, preserves his dignity and the alliance.
Why Not Clozapine
The registry found clozapine associated with the lowest rehospitalization (Tiihonen et al., 2017). Mr. K.'s relapses stem from nonadherence rather than treatment resistance; when he takes risperidone, he does well. Clozapine would add intensive monitoring without addressing the actual cause. It remains an option if he relapses despite reliable delivery.
Missed Injections
If he misses an injection, the long half-life of paliperidone provides some protection, but the clinic will call him and reschedule promptly, and his sister will be informed with his consent.
Monitoring
Weight, glucose, lipids and prolactin-related symptoms are monitored, along with movement disorders using a structured scale. Symptoms and functioning are reviewed monthly.
Beyond Medication
Relapse prevention also includes psychoeducation for Mr. K. and his sister about early warning signs, such as sleep changes and suspiciousness, supported employment to maintain his job and cognitive behavioral therapy for psychosis if persistent symptoms remain.
Work and Daily Life
Monthly clinic visits can be scheduled around his hardware store shifts. Stable symptoms help him keep a job he values, which in turn supports his recovery and self-esteem.
His Sister's Role
His sister will help with reminders for the monthly appointment and watch for early signs of relapse, such as sleeping poorly or withdrawing, calling the clinic if she notices them.
Documentation
The note records the pattern of relapses, the evidence discussed, his choice and the monitoring plan, supporting continuity if he sees another prescriber.
Reassessing the Decision
After six months, we will review whether he has remained well, how he feels about the injections and whether any side effects have emerged, adjusting the plan with him.
Cost and Coverage
Long-acting injectables are more expensive than generic oral risperidone. His insurance covers paliperidone palmitate with prior authorization, which the clinic submits, citing his repeated hospitalizations. Fewer admissions typically offset the higher drug cost.
Negative Symptoms and Cognition
Antipsychotics mainly address positive symptoms. His low motivation and difficulty concentrating at work may need other approaches, such as cognitive remediation and supported employment.
Side Effects Specific to Paliperidone
Paliperidone can raise prolactin, causing sexual side effects or breast changes, and can cause movement symptoms. I ask about these at each visit, since unaddressed side effects are a common reason for stopping any antipsychotic.
Psychosocial Supports
A case manager helps with housing stability and benefits, and a peer support specialist, someone with lived experience of schizophrenia, meets him monthly. Peer support can strengthen engagement in ways clinicians cannot.
Respecting His Choice
If Mr. K. had declined the injectable, I would have respected his decision and used other supports, such as pill organizers, daily text reminders and weekly check-ins, while keeping the option open. Shared decision making means the choice can be revisited.
Early Warning Plan
Mr. K. and his sister write down his personal early warning signs, poor sleep, feeling watched and skipping meals, and the steps to take, including calling the clinic the same day. A written plan turns vague worry into action.
Physical Health
Smoking, weight and blood pressure are addressed at the same visits as his injections, since people with schizophrenia have high rates of cardiovascular disease and die younger than the general population.
Timeline
The first injection is given this week, the second one week later and monthly doses after that.
Conclusion
Maintenance antipsychotics sharply reduce relapse, and the question for Mr. K. is how to ensure he receives them. Randomized trials show no overall advantage for injectables, but a national registry of real-world patients shows substantially lower rehospitalization, and Mr. K.'s history of relapse after stopping pills makes the registry evidence more applicable. Through shared decision making, he chose monthly paliperidone palmitate, with monitoring and psychosocial supports.
References
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophrenia Bulletin, 40(1), 192-213. https://doi.org/10.1093/schbul/sbs150
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063-2071. https://doi.org/10.1016/S0140-6736(12)60239-6
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., & Taipale, H. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686-693. https://doi.org/10.1001/jamapsychiatry.2017.1322
How this PMH 504 Week 4 example is structured
The PMH/504 Week 4 work usually covers long-term antipsychotic management in schizophrenia. This paper uses a common dilemma to show how evidence from different designs is weighed, and how the patient's own history decides which evidence applies. Students search this week as PMH 504 Week 4, PMH504 Wk 4 or PMH/504 Wk 4; all three are the same assignment.
PMH/504 Week 4 questions, answered
What does PMH/504 Week 4 usually ask for?
Many sections ask students to plan long-term antipsychotic management in schizophrenia, including maintenance, adherence, side effects and relapse prevention.
Do long-acting injectables prevent relapse better than pills?
Randomized trials pooled in a meta-analysis did not show an overall advantage, but a national cohort found long-acting injectables associated with substantially lower rehospitalization than the same drugs taken orally, likely because real-world adherence is poorer than in trials.
How much does maintenance treatment reduce relapse?
A meta-analysis found relapse at one year in about 27% of patients on antipsychotics compared with 64% on placebo.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.